|Free Dividend Report|
|Stock Splits Calendar|
|PLX Stock Split History|
|Preferred Stock Newsletter|
|PLX Options Chain|
|PLX Message Board|
Protalix BioTherapeutics (PLX) has 3 splits in our PLX split history database. The first split for PLX took place on December 05, 1991. This was a 4 for 3 split, meaning for each 3 shares of PLX owned pre-split, the shareholder now owned 4 shares. For example, a 1000 share position pre-split, became a 1333.33333333333 share position following the split. PLX's second split took place on August 14, 1992. This was a 3 for 2 split, meaning for each 2 shares of PLX owned pre-split, the shareholder now owned 3 shares. For example, a 1333.33333333333 share position pre-split, became a 2000 share position following the split. PLX's third split took place on December 20, 2019. This was a 1 for 10 reverse split, meaning for each 10 shares of PLX owned pre-split, the shareholder now owned 1 share. For example, a 2000 share position pre-split, became a 200 share position following the split.
When a company such as Protalix BioTherapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. When a company such as Protalix BioTherapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the PLX split history from start to finish, an original position size of 1000 shares would have turned into 200 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Protalix BioTherapeutics shares, starting with a $10,000 purchase of PLX, presented on a split-history-adjusted basis factoring in the complete PLX split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-34.62%|
|About Protalix BioTherapeutics|
|Protalix BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company. Co.'s proprietary ProCellEx platform is being used to manufacture its marketed product, Elelyso®, for the treatment of Gaucher disease. Co. is also developing, via ProCellEx, a pipeline of products. Co.'s clinical development program for pegunigalsidase alfa, or PRX-102, for the potential treatment of Fabry disease. Co. is developing uricase, or PRX-115, for the treatment of refractory gout, PRX-119, a long action DNase I for the treatment of NETs-related diseases, and a number of other product candidates in early and preclinical development. According to our PLX split history records, Protalix BioTherapeutics has had 3 splits.|
|PLX Split History Table|
|12/05/1991||4 for 3|
|08/14/1992||3 for 2|
|12/20/2019||1 for 10|
|Healthcare Stock Splits|
|PLX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:|